ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
ArriVent BioPharma (AVBP) PT Raised to $36 at Citi
September 10, 2024 11:49 AM EDTCiti analyst Yigal Nochomovitz raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $36.00 (from $30.00) while maintaining a Buy rating.
The analyst comments "Today, AVBP shared data from the Ph1b FURTHER study evaluating firmonertinib in 1L+ EGFR PACC mutations at WCLC. The... More



